Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Influenza Vaccination | Research

Uptake of COVID-19 and influenza vaccines in relation to preexisting chronic conditions in the European countries

Authors: Shangfeng Tang, Lu Ji, Ghose Bishwajit, Shuyan Guo

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

The suboptimal uptake of COVID-19 and influenza vaccines among those with non-communicable chronic diseases is a public health concern, because it poses a higher risk of severe illness for individuals with underlying health conditions, emphasizing the need to address barriers to vaccination and ensure adequate protection for this vulnerable population. In the present study, we aimed to identify whether people with chronic illnesses are more likely to get vaccinated against COVID-19 and influenza in the European Union.

Methods

Cross-sectional data on 49,253 men (n = 20,569) and women (n = 28,684) were obtained from the ninth round of the Survey of Health, Ageing and Retirement in Europe (June – August, 2021). The outcome variables were self-reported COVID-19 and influenza vaccine uptake status. The association between the uptake of the vaccines and six preexisting conditions including high blood pressure, high blood cholesterol, chronic lung disease, diabetes, chronic bronchitis, and asthma was estimated using binary logistic regression methods.

Results

The vaccination coverage for COVID-19 ranged from close to 100% in Denmark (98.2%) and Malta (98.2%) to less than 50% in Bulgaria (19.1%) and Romania (32.7%). The countries with the highest percentage of participants with the influenza vaccine included Malta (66.7%), Spain (63.7%) and the Netherlands (62.5%), and those with the lowest percentage included Bulgaria (3.7%), Slovakia (5.8%) and Poland (9.2%). Participants with high blood pressure were 3% less likely [Risk difference (RD) = -0.03, 95% CI = -0.04, -0.03] to report taking COVID-19 and influenza [RD = -0.03, 95% CI= -0.04, -0.01] vaccine. Those with chronic lung disease were 4% less likely [RD = -0.04, 95% CI= -0.06, -0.03] to report taking COVID-19 and 2% less likely [RD= -0.02, 95% CI = -0.04, -0.01] to report taking influenza vaccine. Men and women with high blood pressure were 3% less likely to have reported taking both of the vaccines.

Conclusions

Current findings indicate a suboptimal uptake of COVID-19 and influenza vaccines among adult men and women in the EU countries. Those with preexisting conditions, including high blood pressure and chronic lung disease are less likely to take the vaccines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rubin R. The dreaded twindemic of Influenza and COVID-19 has not yet materialized—might this be the year? JAMA. 2022;328:1488–9.CrossRefPubMed Rubin R. The dreaded twindemic of Influenza and COVID-19 has not yet materialized—might this be the year? JAMA. 2022;328:1488–9.CrossRefPubMed
2.
go back to reference Du Z, Fox SJ, Ingle T, Pignone MP, Meyers LA. Projecting the Combined Health Care Burden of Seasonal Influenza and COVID-19 in the 2020–2021 season. MDM Policy Pract. 2022;7:23814683221084631.PubMedPubMedCentral Du Z, Fox SJ, Ingle T, Pignone MP, Meyers LA. Projecting the Combined Health Care Burden of Seasonal Influenza and COVID-19 in the 2020–2021 season. MDM Policy Pract. 2022;7:23814683221084631.PubMedPubMedCentral
4.
go back to reference GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to Influenza Lower Respiratory Tract Infections, 2017: an analysis for the global burden of Disease Study 2017. Lancet Respir Med. 2019;7:69–89.CrossRef GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to Influenza Lower Respiratory Tract Infections, 2017: an analysis for the global burden of Disease Study 2017. Lancet Respir Med. 2019;7:69–89.CrossRef
5.
go back to reference Macias AE, McElhaney JE, Chaves SS, Nealon J, Nunes MC, Samson SI, et al. The Disease burden of Influenza beyond respiratory Illness. Vaccine. 2021;39:A6–14.CrossRefPubMed Macias AE, McElhaney JE, Chaves SS, Nealon J, Nunes MC, Samson SI, et al. The Disease burden of Influenza beyond respiratory Illness. Vaccine. 2021;39:A6–14.CrossRefPubMed
6.
go back to reference Walzer P, Estève C, Barben J, Menu D, Cuenot C, Manckoundia P, et al. Impact of Influenza Vaccination on Mortality in the Oldest Old: a propensity score-matched cohort study. Vaccines. 2020;8:356.CrossRefPubMedPubMedCentral Walzer P, Estève C, Barben J, Menu D, Cuenot C, Manckoundia P, et al. Impact of Influenza Vaccination on Mortality in the Oldest Old: a propensity score-matched cohort study. Vaccines. 2020;8:356.CrossRefPubMedPubMedCentral
7.
go back to reference Godoy P, Romero A, Soldevila N, Torner N, Jané M, Martínez A, et al. Influenza vaccine effectiveness in reducing severe outcomes over six Influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Eurosurveillance. 2018;23:1700732.CrossRefPubMedPubMedCentral Godoy P, Romero A, Soldevila N, Torner N, Jané M, Martínez A, et al. Influenza vaccine effectiveness in reducing severe outcomes over six Influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Eurosurveillance. 2018;23:1700732.CrossRefPubMedPubMedCentral
8.
go back to reference Strain WD, Mansi J, Boikos C, Boivin M, Fisher WA. Achieving Influenza Vaccine Uptake Target in Canada via a pharmacy-led telephone discussion during the 2019–2020 season. Vaccines. 2021;9:312.CrossRefPubMedPubMedCentral Strain WD, Mansi J, Boikos C, Boivin M, Fisher WA. Achieving Influenza Vaccine Uptake Target in Canada via a pharmacy-led telephone discussion during the 2019–2020 season. Vaccines. 2021;9:312.CrossRefPubMedPubMedCentral
9.
go back to reference Blanchi S, Torreggiani M, Chatrenet A, Fois A, Mazé B, Njandjo L, et al. COVID-19 vaccine hesitancy in patients on Dialysis in Italy and France. Kidney Int Rep. 2021;6:2763–74.CrossRefPubMedPubMedCentral Blanchi S, Torreggiani M, Chatrenet A, Fois A, Mazé B, Njandjo L, et al. COVID-19 vaccine hesitancy in patients on Dialysis in Italy and France. Kidney Int Rep. 2021;6:2763–74.CrossRefPubMedPubMedCentral
10.
go back to reference Smith BA, Ricotta EE, Kwan JL, Evans NG. COVID-19 risk perception and vaccine acceptance in individuals with chronic Disease. medRxiv. 2022. 2021.03.17.21253760. Smith BA, Ricotta EE, Kwan JL, Evans NG. COVID-19 risk perception and vaccine acceptance in individuals with chronic Disease. medRxiv. 2022. 2021.03.17.21253760.
11.
go back to reference Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, et al. Preexisting immunity, more Than Aging, influences Influenza vaccine responses. Open Forum Infect Dis. 2015;2:ofv052.CrossRefPubMedPubMedCentral Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, et al. Preexisting immunity, more Than Aging, influences Influenza vaccine responses. Open Forum Infect Dis. 2015;2:ofv052.CrossRefPubMedPubMedCentral
12.
go back to reference Keenan H, Campbell J, Evans PH. Influenza vaccination in patients with Asthma: why is the uptake so low? Br J Gen Pract. 2007;57:359–63.PubMedPubMedCentral Keenan H, Campbell J, Evans PH. Influenza vaccination in patients with Asthma: why is the uptake so low? Br J Gen Pract. 2007;57:359–63.PubMedPubMedCentral
13.
go back to reference Singleton JA, Wortley P, Lu P-J. Influenza vaccination of persons with Cardiovascular Disease in the United States. Tex Heart Inst J. 2004;31:22–7.PubMedPubMedCentral Singleton JA, Wortley P, Lu P-J. Influenza vaccination of persons with Cardiovascular Disease in the United States. Tex Heart Inst J. 2004;31:22–7.PubMedPubMedCentral
14.
go back to reference Fekete M, Pako J, Nemeth AN, Tarantini S, Varga JT. Prevalence of Influenza and pneumococcal vaccination in Chronic Obstructive Pulmonary Disease patients in association with the occurrence of acute exacerbations. J Thorac Dis. 2020;12:4233–42.CrossRefPubMedPubMedCentral Fekete M, Pako J, Nemeth AN, Tarantini S, Varga JT. Prevalence of Influenza and pneumococcal vaccination in Chronic Obstructive Pulmonary Disease patients in association with the occurrence of acute exacerbations. J Thorac Dis. 2020;12:4233–42.CrossRefPubMedPubMedCentral
15.
go back to reference Zamorano-Leon JJ, Jimenez-Garcia R, Lopez-de-Andres A, de-Miguel-Diez J, Carabantes-Alarcon D, Albaladejo-Vicente R, et al. Low levels of Influenza Vaccine Uptake among the Diabetic Population in Spain: a Time Trend Study from 2011 to 2020. J Clin Med. 2021;11:68.CrossRefPubMedPubMedCentral Zamorano-Leon JJ, Jimenez-Garcia R, Lopez-de-Andres A, de-Miguel-Diez J, Carabantes-Alarcon D, Albaladejo-Vicente R, et al. Low levels of Influenza Vaccine Uptake among the Diabetic Population in Spain: a Time Trend Study from 2011 to 2020. J Clin Med. 2021;11:68.CrossRefPubMedPubMedCentral
16.
go back to reference Song Z, Liu X, Xiang P, Lin Y, Dai L, Guo Y, et al. The current status of Vaccine Uptake and the impact of COVID-19 on intention to vaccination in patients with COPD in Beijing. Int J Chron Obstruct Pulmon Dis. 2021;16:3337–46.CrossRefPubMedPubMedCentral Song Z, Liu X, Xiang P, Lin Y, Dai L, Guo Y, et al. The current status of Vaccine Uptake and the impact of COVID-19 on intention to vaccination in patients with COPD in Beijing. Int J Chron Obstruct Pulmon Dis. 2021;16:3337–46.CrossRefPubMedPubMedCentral
17.
go back to reference Wang Y, Duan L, Li M, Wang J, Yang J, Song C, et al. COVID-19 vaccine hesitancy and Associated Factors among Diabetes patients: a cross-sectional survey in Changzhi, Shanxi, China. Vaccines. 2022;10:129.CrossRefPubMedPubMedCentral Wang Y, Duan L, Li M, Wang J, Yang J, Song C, et al. COVID-19 vaccine hesitancy and Associated Factors among Diabetes patients: a cross-sectional survey in Changzhi, Shanxi, China. Vaccines. 2022;10:129.CrossRefPubMedPubMedCentral
18.
go back to reference Asadi-Pooya AA, Barzegar Z, Sadeghian S, Nezafat A, Shahisavandi M, Nabavizadeh SA. COVID-19 vaccine hesitancy among patients with Epilepsy or other chronic conditions. Disaster Med Public Health Prep.:1–3. Asadi-Pooya AA, Barzegar Z, Sadeghian S, Nezafat A, Shahisavandi M, Nabavizadeh SA. COVID-19 vaccine hesitancy among patients with Epilepsy or other chronic conditions. Disaster Med Public Health Prep.:1–3.
19.
go back to reference Popa AD, Enache AI, Popa IV, Antoniu SA, Dragomir RA, Burlacu A. Determinants of the hesitancy toward COVID-19 Vaccination in Eastern European Countries and the relationship with health and vaccine literacy: a Literature Review. Vaccines. 2022;10:672.CrossRefPubMedPubMedCentral Popa AD, Enache AI, Popa IV, Antoniu SA, Dragomir RA, Burlacu A. Determinants of the hesitancy toward COVID-19 Vaccination in Eastern European Countries and the relationship with health and vaccine literacy: a Literature Review. Vaccines. 2022;10:672.CrossRefPubMedPubMedCentral
20.
go back to reference Heyerdahl LW, Vray M, Lana B, Tvardik N, Gobat N, Wanat M, et al. Conditionality of COVID-19 vaccine acceptance in European countries. Vaccine. 2022;40:1191–7.CrossRefPubMedPubMedCentral Heyerdahl LW, Vray M, Lana B, Tvardik N, Gobat N, Wanat M, et al. Conditionality of COVID-19 vaccine acceptance in European countries. Vaccine. 2022;40:1191–7.CrossRefPubMedPubMedCentral
21.
go back to reference Karafillakis E, Van Damme P, Hendrickx G, Larson HJ. COVID-19 in Europe: new challenges for addressing vaccine hesitancy. Lancet Lond Engl. 2022;399:699–701.CrossRef Karafillakis E, Van Damme P, Hendrickx G, Larson HJ. COVID-19 in Europe: new challenges for addressing vaccine hesitancy. Lancet Lond Engl. 2022;399:699–701.CrossRef
22.
go back to reference Liotta G, Canhao H, Cenko F, Cutini R, Vellone E, Illario M, et al. Active ageing in Europe: adding healthy life to years. Front Med. 2018;5:123.CrossRef Liotta G, Canhao H, Cenko F, Cutini R, Vellone E, Illario M, et al. Active ageing in Europe: adding healthy life to years. Front Med. 2018;5:123.CrossRef
23.
go back to reference Börsch-Supan A. Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 9. COVID-19 Survey 2. 2022. Börsch-Supan A. Survey of Health, Ageing and Retirement in Europe (SHARE) Wave 9. COVID-19 Survey 2. 2022.
24.
go back to reference Zintel S, Flock C, Arbogast AL, Forster A, von Wagner C, Sieverding M. Gender differences in the intention to get vaccinated against COVID-19: a systematic review and meta-analysis. Z Gesundheitswissenschaften. 2022;:1–25. Zintel S, Flock C, Arbogast AL, Forster A, von Wagner C, Sieverding M. Gender differences in the intention to get vaccinated against COVID-19: a systematic review and meta-analysis. Z Gesundheitswissenschaften. 2022;:1–25.
25.
go back to reference Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S et al. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccines Immunother 17:3975–81. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S et al. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Hum Vaccines Immunother 17:3975–81.
26.
go back to reference Steinert JI, Sternberg H, Prince H, Fasolo B, Galizzi MM, Büthe T et al. COVID-19 vaccine hesitancy in eight European countries: prevalence, determinants, and heterogeneity. Sci Adv 8:eabm9825. Steinert JI, Sternberg H, Prince H, Fasolo B, Galizzi MM, Büthe T et al. COVID-19 vaccine hesitancy in eight European countries: prevalence, determinants, and heterogeneity. Sci Adv 8:eabm9825.
27.
go back to reference Guralnik JM, Balfour JL, Volpato S. The ratio of older women to men: historical perspectives and cross-national comparisons. Aging Milan Italy. 2000;12:65–76.PubMed Guralnik JM, Balfour JL, Volpato S. The ratio of older women to men: historical perspectives and cross-national comparisons. Aging Milan Italy. 2000;12:65–76.PubMed
30.
go back to reference Fabião J, Sassi B, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, et al. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res. 2022;55:e11711.CrossRefPubMedPubMedCentral Fabião J, Sassi B, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, et al. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res. 2022;55:e11711.CrossRefPubMedPubMedCentral
31.
go back to reference Zhang D, Zhou W, Poon PK-M, Kwok KO, Chui TW-S, Hung PHY, et al. Vaccine resistance and hesitancy among older adults who live alone or only with an Older Partner in Community in the early stage of the Fifth Wave of COVID-19 in Hong Kong. Vaccines. 2022;10:1118.CrossRefPubMedPubMedCentral Zhang D, Zhou W, Poon PK-M, Kwok KO, Chui TW-S, Hung PHY, et al. Vaccine resistance and hesitancy among older adults who live alone or only with an Older Partner in Community in the early stage of the Fifth Wave of COVID-19 in Hong Kong. Vaccines. 2022;10:1118.CrossRefPubMedPubMedCentral
Metadata
Title
Uptake of COVID-19 and influenza vaccines in relation to preexisting chronic conditions in the European countries
Authors
Shangfeng Tang
Lu Ji
Ghose Bishwajit
Shuyan Guo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-023-04623-5

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine